The genetic-testing company hit a buzz saw when it downgraded its 2019 earnings forecast earlier this year following a slowdown in the consumer market. But the fact remains that Illumina’s platforms dominate the genomic sequencing space (its technology has helped slash the cost of whole genomic sequencing to mere thousands of dollars while considerably speeding up the process).The $44 billion company has “demonstrated an uncanny ability to out-innovate and extend its competitive lead,” according to J.P. Morgan.
Subscribe to Fortune's Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.
|Industry||Life Sciences Tools and Services|
|HQ Location||San Diego|
|Revenues ($M) (Past 12 Months)||$3,404|
|Profits ($M) (Past 12 Months)||$938|
|Market Value as of Oct. 9, 2019 ($M)||$43,653|